The effects of the plasticizer poly（ethylene glycol） （PEG） on crystallization properties of equimolar poly（L-lactide） （PLLA）/poly（D-lactide） （PDLA） blends were investigated. Forma- tion of the stereocomple...The effects of the plasticizer poly（ethylene glycol） （PEG） on crystallization properties of equimolar poly（L-lactide） （PLLA）/poly（D-lactide） （PDLA） blends were investigated. Forma- tion of the stereocomplex-type poly（lactide acid） （sc-PLA） crystallites was confirmed by Wide-angle X-ray diffraction （WAXD） and differential scanning calorimetry （DSC） analyses. Sc-PLA crystallites without any homochiral poly（lactide acid） （hc-PLA） formed, as the result of the incorporation of the plasticizer PEG （more than or equal to 10%（wt）） at a processing temperature （240 ℃）. More-over, when the Mw of PEG reached 1 000 g · mol^-1, the crystal- lizability of stereocomplex crystallites was the best. Isothermal crystallization kinetics further revealed that PEG could accelerate the crystallization rate of sc-PLA, with the optimum crystallization kinetic parameters being obtained at 10% （wt） PEG. Several crys- tallization kinetics equations were applied to describe the effect of PEG on the crystallization behavior of sc-PLA. The influence of PEG on the spherocrystal morphologies of sc-PLA was also inves- tigated using polarized optical microscopy.展开更多
目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能...目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能。采用激光粒度分析仪、扫描电子显微镜和X射线衍射法对该微球进行表征。结果:选取内水相体积300μL,PLGA质量浓度125 g·L^(-1),二氯甲烷-丙酮(3∶7),外油相为液体石蜡200 m L,加入正己烷6 m L,0.25%司盘80为乳化剂,1 400 r·min^(-1)搅拌4 h。丹参素钠-PLGA微球平均载药量(20.71±1.42)%,平均包封率(63.27±1.70)%,平均收率(99.10±0.83)%,体外累积释放率达98%需要120 h。平均粒径(71.72±1.71)μm,表面圆整光滑,内部含有蜂窝状孔洞。部分药物可能以晶体状态分散于载体材料中。结论:W/O/O型乳化溶剂挥发法成功制备了丹参素钠-PLGA微球,优选的处方工艺稳定合理,可为丹参素钠制剂的开发提供参考。展开更多
基金Supported by the National Natural Science Foundation of China(51403160)the Opening Project of Hubei Key Laboratory Biomass Fibers and Eco-dyeing&Finishing(STRZ2017009)
文摘The effects of the plasticizer poly（ethylene glycol） （PEG） on crystallization properties of equimolar poly（L-lactide） （PLLA）/poly（D-lactide） （PDLA） blends were investigated. Forma- tion of the stereocomplex-type poly（lactide acid） （sc-PLA） crystallites was confirmed by Wide-angle X-ray diffraction （WAXD） and differential scanning calorimetry （DSC） analyses. Sc-PLA crystallites without any homochiral poly（lactide acid） （hc-PLA） formed, as the result of the incorporation of the plasticizer PEG （more than or equal to 10%（wt）） at a processing temperature （240 ℃）. More-over, when the Mw of PEG reached 1 000 g · mol^-1, the crystal- lizability of stereocomplex crystallites was the best. Isothermal crystallization kinetics further revealed that PEG could accelerate the crystallization rate of sc-PLA, with the optimum crystallization kinetic parameters being obtained at 10% （wt） PEG. Several crys- tallization kinetics equations were applied to describe the effect of PEG on the crystallization behavior of sc-PLA. The influence of PEG on the spherocrystal morphologies of sc-PLA was also inves- tigated using polarized optical microscopy.
文摘目的:优选丹参素钠-聚乳酸-羟基乙酸共聚物(PLGA)缓释微球的处方工艺并考察其药剂学性能。方法:采用W/O/O型乳化溶剂挥发法制备丹参素钠-PLGA微球,以载药量、包封率及收率为考察指标,通过单因素试验优选处方工艺,并考察其体外释药性能。采用激光粒度分析仪、扫描电子显微镜和X射线衍射法对该微球进行表征。结果:选取内水相体积300μL,PLGA质量浓度125 g·L^(-1),二氯甲烷-丙酮(3∶7),外油相为液体石蜡200 m L,加入正己烷6 m L,0.25%司盘80为乳化剂,1 400 r·min^(-1)搅拌4 h。丹参素钠-PLGA微球平均载药量(20.71±1.42)%,平均包封率(63.27±1.70)%,平均收率(99.10±0.83)%,体外累积释放率达98%需要120 h。平均粒径(71.72±1.71)μm,表面圆整光滑,内部含有蜂窝状孔洞。部分药物可能以晶体状态分散于载体材料中。结论:W/O/O型乳化溶剂挥发法成功制备了丹参素钠-PLGA微球,优选的处方工艺稳定合理,可为丹参素钠制剂的开发提供参考。
